{"id":4086,"date":"2026-10-28T22:00:00","date_gmt":"2026-10-28T14:00:00","guid":{"rendered":"https:\/\/www.junshipharma.com\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"modified":"2026-11-02T16:55:52","modified_gmt":"2026-11-02T08:55:52","slug":"junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma","status":"publish","type":"post","link":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma"},"content":{"rendered":"\n

SHANGHAI, China, October 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company\u2019s product, toripalimab injection (subcutaneous injection) (code: JS001sc) in combination with disitamab vedotin for the treatment of HER2-expressing (HER2 expression is defined as HER2 immunohistochemistry results of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma (UC) has recently been accepted by the China National Medical Products Administration (NMPA). To date, the new drug application for JS001sc, in respect of all 13 approved indications<\/strong><\/strong> of toripalimab (intravenous injection) (code: JS001), have been accepted.<\/p>\n\n\n\n

Immuno-oncology (I-O) therapies, represented by anti-PD-1 monoclonal antibodies, have become cornerstone therapies for the treatment of various malignant tumors. However, immuno-oncology drugs currently available in China are predominantly formulated for intravenous infusion, which not only requires prolonged infusion times but also causes significant inconvenience to patients during treatment. Consequently, there is an urgent clinical need to improve the convenience of immunotherapy.<\/p>\n\n\n\n

JS001sc is a subcutaneous injection formulation developed by Junshi Biosciences based on the marketed product, toripalimab injection. It is the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the new drug application stage, and is expected to bring convenient administration to patients. In November 2025, a multi-center, open-label, randomized controlled Phase 3 clinical study to compare JS001sc and toripalimab injection in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer met the primary endpoint. <\/p>\n\n\n\n

In March 2026, the Phase 3 clinical study of JS001sc in combination with chemotherapy as a first-line treatment for non-squamous non-small-cell lung cancer was successfully selected for an oral presentation at the European Lung Cancer Congress 2026 (ELCC 2026). The study results demonstrated that the drug exposure of toripalimab subcutaneous injection was non-inferior to that of the intravenous formulation of toripalimab, with comparable clinical efficacy and safety profiles, and is expected to provide patients with a new, more convenient immunotherapy option.<\/p>\n\n\n\n

In March 2026, the new drug application of JS001sc for 12 indications for the treatment of tumors was accepted by the NMPA, making it the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the new drug application stage.<\/p>\n\n\n\n


\u3010Reference\u3011<\/h5>\n\n\n\n
1.Wu L, et al. Subcutaneous versus intravenous toripalimab, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic non-squamous (nsq) non-small cell lung cancer (NSCLC): A randomized phase III trial. Presented at: 2026 European Lung Cancer Congress (ELCC); March 25\u201328, 2026; Copenhagen, Denmark. Abstract 8MO.<\/h5>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

To date, the new drug application for JS001sc, in respect of all 13 approved indications of toripalimab (intravenous injection) (JS001), have been accepted.<\/p>\n","protected":false},"author":6,"featured_media":3871,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[97,96,130],"class_list":["post-4086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-pd-1-en","tag-urothelial-carcinoma","tag--en"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"description\" content=\"The 13th sNDA for toripalimab injection (subcutaneous injection) has recently been accepted by the China NMPA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"The 13th sNDA for toripalimab injection (subcutaneous injection) has recently been accepted by the China NMPA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T14:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T08:55:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"766\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u5389, \u667a\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u5389, \u667a\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"},\"author\":{\"name\":\"\u5389, \u667a\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma\",\"datePublished\":\"2026-10-28T14:00:00+00:00\",\"dateModified\":\"2026-11-02T08:55:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"},\"wordCount\":444,\"publisher\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg\",\"keywords\":[\"PD-1\",\"Urothelial Carcinoma\",\"\u7279\u745e\u666e\u5229\u5355\u6297\uff08\u76ae\u4e0b\u6ce8\u5c04\uff09\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\",\"url\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg\",\"datePublished\":\"2026-10-28T14:00:00+00:00\",\"dateModified\":\"2026-11-02T08:55:52+00:00\",\"description\":\"The 13th sNDA for toripalimab injection (subcutaneous injection) has recently been accepted by the China NMPA.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage\",\"url\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg\",\"contentUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg\",\"width\":1800,\"height\":766},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/#website\",\"url\":\"https:\/\/www.junshipharma.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.junshipharma.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"https:\/\/www.junshipharma.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"https:\/\/www.junshipharma.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.junshipharma.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\",\"name\":\"\u5389, \u667a\",\"url\":\"https:\/\/www.junshipharma.com\/en\/author\/zhi_li\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269","description":"The 13th sNDA for toripalimab injection (subcutaneous injection) has recently been accepted by the China NMPA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269","og_description":"The 13th sNDA for toripalimab injection (subcutaneous injection) has recently been accepted by the China NMPA.","og_url":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2026-10-28T14:00:00+00:00","article_modified_time":"2026-11-02T08:55:52+00:00","og_image":[{"width":1800,"height":766,"url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg","type":"image\/jpeg"}],"author":"\u5389, \u667a","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u5389, \u667a","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#article","isPartOf":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"author":{"name":"\u5389, \u667a","@id":"https:\/\/www.junshipharma.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma","datePublished":"2026-10-28T14:00:00+00:00","dateModified":"2026-11-02T08:55:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"},"wordCount":444,"publisher":{"@id":"https:\/\/www.junshipharma.com\/en\/#organization"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg","keywords":["PD-1","Urothelial Carcinoma","\u7279\u745e\u666e\u5229\u5355\u6297\uff08\u76ae\u4e0b\u6ce8\u5c04\uff09"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","url":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"https:\/\/www.junshipharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg","datePublished":"2026-10-28T14:00:00+00:00","dateModified":"2026-11-02T08:55:52+00:00","description":"The 13th sNDA for toripalimab injection (subcutaneous injection) has recently been accepted by the China NMPA.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.junshipharma.com\/en\/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma\/#primaryimage","url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg","contentUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2026\/05\/JS001sc.jpg","width":1800,"height":766},{"@type":"WebSite","@id":"https:\/\/www.junshipharma.com\/en\/#website","url":"https:\/\/www.junshipharma.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"https:\/\/www.junshipharma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.junshipharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.junshipharma.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"https:\/\/www.junshipharma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.junshipharma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"https:\/\/www.junshipharma.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.junshipharma.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4","name":"\u5389, \u667a","url":"https:\/\/www.junshipharma.com\/en\/author\/zhi_li\/"}]}},"_links":{"self":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/4086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/comments?post=4086"}],"version-history":[{"count":2,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/4086\/revisions"}],"predecessor-version":[{"id":4092,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/posts\/4086\/revisions\/4092"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/media\/3871"}],"wp:attachment":[{"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/media?parent=4086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/categories?post=4086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.junshipharma.com\/en\/wp-json\/wp\/v2\/tags?post=4086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}